• PTC Therapeutics entered an asset purchase agreement to buy Sangamo’s ST-920 gene therapy program for Fabry disease.
• Deal terms include an upfront payment of $111 million, with up to $100 million tied to FDA accelerated approval and full approval milestones.
• Closing hinges on Delaware bankruptcy court authorization, Hart-Scott-Rodino clearance, and other customary conditions.
• A bankruptcy court hearing on the transaction is scheduled for Sept. 10, 2026, with an outside closing date of Oct. 15, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001070081-26-000019), on August 28, 2026, and is solely responsible for the information contained therein.